RxDoctor Payments Data

Chelsey Moore, PA

Physician Assistant · Charlotte, NCNPI 1568883320

Payments from drug & device makers

$6,892in general payments, 2019–2025

Across 324 payments — averaging $21.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • AstraZeneca$1K
  • Novartis$1K
  • Amgen$580
  • Abiomed$481
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$446
  • plus $2K from 17 others

What the payments were for

  • Food & beverage$6,892100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,892 in reported general payments places this provider in the 95th percentile of 7,441 physician assistant providers in North Carolina.

See all physician assistant providers in North Carolina

Medicare billing

Part B allowed, 2024
$5,636
Medicare patients
55
Services billed
73

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban45$41,293
BrilintaTicagrelor62$28,937
XareltoRivaroxaban28$26,754
EntrestoSacubitril/Valsartan35$24,301
JardianceEmpagliflozin26$20,355
FarxigaDapagliflozin Propanediol23$17,970
Repatha SureclickEvolocumab24$14,722
Repatha SyringeEvolocumab11$7,917
Ranolazine ErRanolazine13$1,031
Rosuvastatin Calcium55$793
ClopidogrelClopidogrel Bisulfate132$770
Atorvastatin Calcium59$587
Ezetimibe38$511
Metoprolol Succinate55$366
Amlodipine Besylate39$283

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBrilinta, Farxiga$1,033$46,90885 claims
Johnson & JohnsonXarelto$1,076$26,75428 claims
NovartisEntresto$1,015$24,30135 claims
Boehringer IngelheimJardiance$152$20,35526 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,441 physician assistant providers in North Carolina.

Other physician assistant in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →